AllAnalyst Report
Morningstar•March 18, 2024
Morningstar•March 18, 2024Boston Scientific Corporation: Boston Scientific Is Poised to Accelerate Its Atrial Fibrillation Ablation Business in 2024
Summary
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm mar
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Daily – Vickers Top Buyers & Sellers for 04/26/2024Apr 26, 2024 •
VIVK, AUID, BHVN, TBLD, ZWS, INTZ, AXP, JEF, ELV, DHR
- Analyst Report: Bristol-Myers Squibb CompanyApr 25, 2024 •
BMY
- Analyst Report: Intuitive Surgical IncApr 25, 2024 •
ISRG
- Market Update: CMG, ISRG, MAT, NOKApr 25, 2024 •
MAT, NOK, CMG, ISRG
- Analyst Report: Biogen Inc.Apr 24, 2024 •
BIIB
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.